|
US5965132A
(en)
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
US6749853B1
(en)
|
1992-03-05 |
2004-06-15 |
Board Of Regents, The University Of Texas System |
Combined methods and compositions for coagulation and tumor treatment
|
|
GB9610967D0
(en)
|
1996-05-24 |
1996-07-31 |
Cambridge Antibody Tech |
Specific binding members,materials and methods
|
|
WO2000040262A1
(en)
*
|
1999-01-05 |
2000-07-13 |
The Flinders University Of South Australia |
Novel agents and methods for treatment and diagnosis of ocular disorders
|
|
DE19932688B4
(de)
|
1999-07-13 |
2009-10-08 |
Scil Proteins Gmbh |
Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
|
|
DE19947559A1
(de)
*
|
1999-09-24 |
2001-04-19 |
Schering Ag |
Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
|
|
US6319273B1
(en)
*
|
1999-12-16 |
2001-11-20 |
Light Sciences Corporation |
Illuminating device for treating eye disease
|
|
JP2003524018A
(ja)
*
|
2000-02-24 |
2003-08-12 |
アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ |
フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
|
|
AU2001239470A1
(en)
|
2000-02-24 |
2001-09-03 |
Philogen S.R.L. |
Compositions and methods for treatment of angiogenesis in pathological lesions
|
|
CN1246333C
(zh)
*
|
2000-09-07 |
2006-03-22 |
舍林股份公司 |
EDb－纤粘连蛋白结构域(II)的受体
|
|
DE10045803A1
(de)
*
|
2000-09-07 |
2002-04-11 |
Schering Ag |
Rezeptor der EDb Fibronektin-Domäne
|
|
US20030100010A1
(en)
*
|
2001-11-23 |
2003-05-29 |
George Jackowski |
Fibrinogen biopolymer Marker predictive of type II diabetes
|
|
EP1453546A2
(en)
*
|
2001-12-04 |
2004-09-08 |
Nanospectra Biosciences, Inc. |
Treatment of angiogenesis disorders using targeted nanoparticles
|
|
DK1461360T3
(da)
*
|
2002-01-03 |
2010-11-15 |
Bayer Schering Pharma Ag |
Konjugater omfattende et antistofspecifik for ED-8-domæner af fibronectin og deres anvendelse til påvisning og behandling af tumorer
|
|
MXPA04006517A
(es)
|
2002-01-03 |
2005-03-31 |
Schering Ag |
Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
|
|
EP2174958A1
(en)
*
|
2002-03-11 |
2010-04-14 |
Philogen S.p.A. |
Antibodies derived from anti ed-b l19 and targeting tumor vasculature
|
|
KR20120068769A
(ko)
|
2002-07-15 |
2012-06-27 |
더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 |
음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
|
|
DE10324447A1
(de)
|
2003-05-28 |
2004-12-30 |
Scil Proteins Gmbh |
Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
|
|
DE10348319A1
(de)
*
|
2003-10-17 |
2005-05-19 |
Schering Ag |
Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques
|
|
US7785591B2
(en)
|
2004-10-14 |
2010-08-31 |
Morphosys Ag |
Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
|
|
ES2577292T3
(es)
*
|
2005-11-07 |
2016-07-14 |
Genentech, Inc. |
Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
|
|
ATE463512T1
(de)
*
|
2005-11-09 |
2010-04-15 |
Morphosys Ag |
Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
|
|
EP1842553A1
(en)
*
|
2006-04-07 |
2007-10-10 |
Bayer Schering Pharma Aktiengesellschaft |
Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
|
|
EP1925664A1
(en)
|
2006-11-15 |
2008-05-28 |
Scil proteins GmbH |
Artificial binding proteins based on a modified alpha helical region of ubiquitin
|
|
ATE548052T1
(de)
|
2008-01-17 |
2012-03-15 |
Philogen Spa |
Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
|
|
EP2100621A1
(en)
|
2008-03-10 |
2009-09-16 |
mivenion GmbH |
Polyether polyol dendron conjugates with effector molecules for biological targeting
|
|
JP2009244154A
(ja)
|
2008-03-31 |
2009-10-22 |
Nationa Hospital Organization |
老化、および血管障害を伴う疾患の検定のための組成物、キットおよび方法
|
|
EP2116555A1
(en)
|
2008-05-08 |
2009-11-11 |
Bayer Schering Pharma Aktiengesellschaft |
Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
|
|
US20110306065A1
(en)
*
|
2008-11-12 |
2011-12-15 |
The Trustees Of The University Of Pennsylvania |
Use of an antibody and a rare-earth based crystal
|
|
RU2553333C2
(ru)
|
2009-12-14 |
2015-06-10 |
Сцил Протеинс Гмбх |
Способ идентификации гетеромультимерных модифицированных убиквитиновых белков со способностью связываться с лигандами
|
|
WO2011110490A1
(en)
|
2010-03-09 |
2011-09-15 |
Bayer Pharma Aktiengesellschaft |
Process for the production of radioactively labelled scfv antibody fragments, kits and compositions
|
|
CA2837804C
(en)
|
2011-06-15 |
2018-03-20 |
Scil Proteins Gmbh |
Dimeric binding proteins based on modified ubiquitins
|
|
WO2012171541A1
(en)
|
2011-06-15 |
2012-12-20 |
Scil Proteins Gmbh |
Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
|
|
EP2734232B1
(en)
|
2011-07-19 |
2017-11-01 |
Philogen S.p.A. |
Sequential anti-ctla4 and targeted il-2 therapy
|
|
RU2481839C2
(ru)
*
|
2011-08-16 |
2013-05-20 |
Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет Министерства здравоохранения и социального развития" |
Способ лечения ишемической болезни сердца с дистальным или диффузным поражением коронарных артерий
|
|
EP2861616A1
(en)
|
2012-06-13 |
2015-04-22 |
Scil Proteins GmbH |
Human fusion proteins comprising single chain tnfalpha and targeting domains
|
|
WO2014094799A1
(en)
|
2012-12-19 |
2014-06-26 |
Scil-Proteins-Gmbh |
Ubiquitin moieties as a means for prolonging serum half-life
|
|
CN104395342B
(zh)
*
|
2013-06-06 |
2017-07-04 |
合肥立方制药股份有限公司 |
人源抗纤连蛋白ed‑b结构域的抗体及其用途
|
|
JP6738340B2
(ja)
|
2015-02-06 |
2020-08-12 |
ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ |
新規なｅｇｆｒ結合タンパク質
|
|
JP6856938B2
(ja)
|
2015-07-16 |
2021-04-14 |
ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ |
新規な免疫グロブリン結合タンパク質およびアフィニティ精製におけるそれらの使用
|
|
WO2017013136A1
(en)
|
2015-07-20 |
2017-01-26 |
Scil Proteins Gmbh |
Novel binding proteins based on di-ubiquitin muteins and methods for generation
|
|
WO2017084017A1
(zh)
*
|
2015-11-16 |
2017-05-26 |
合肥立方制药股份有限公司 |
Ed-b蛋白在诊断组织增生中的应用
|
|
US11813336B2
(en)
|
2016-05-04 |
2023-11-14 |
Navigo Proteins Gmbh |
Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
|
|
GB201612317D0
(en)
|
2016-07-15 |
2016-08-31 |
Philogen Spa |
Antibody compositions
|
|
CN109963864B
(zh)
|
2016-08-11 |
2024-01-02 |
瑞普利金公司 |
用于亲和色谱的碱性稳定性fc结合蛋白
|
|
ES3007557T3
(en)
|
2016-10-17 |
2025-03-20 |
Pfizer |
Anti-edb antibodies and antibody-drug conjugates
|
|
GB201621806D0
(en)
|
2016-12-21 |
2017-02-01 |
Philogen Spa |
Immunocytokines with progressive activation mechanism
|
|
CN111148759B
(zh)
*
|
2017-09-30 |
2023-09-19 |
合肥立方制药股份有限公司 |
结合至纤维连接蛋白b结构域的蛋白
|
|
US11414466B2
(en)
|
2017-11-07 |
2022-08-16 |
Navigo Proteins Gmbh |
Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
|
|
WO2019185792A1
(en)
|
2018-03-29 |
2019-10-03 |
Philogen S.P.A |
Cancer treatment using immunoconjugates and immune check-point inhibitors
|
|
EP3660039A1
(en)
|
2018-11-30 |
2020-06-03 |
Philogen S.p.A. |
Il2 immunoconjugates
|
|
WO2020070150A1
(en)
|
2018-10-02 |
2020-04-09 |
Philogen S.P.A |
Il2 immunoconjugates
|
|
MX2021007283A
(es)
|
2018-12-18 |
2021-07-15 |
Navigo Proteins Gmbh |
Proteinas de union especificas del folr1 novedosas para diagnostico y tratamiento del cancer.
|
|
WO2022268983A2
(en)
|
2021-06-23 |
2022-12-29 |
Cytune Pharma |
Interleukin-15 based immunocytokines
|
|
CN117597355A
(zh)
|
2021-06-23 |
2024-02-23 |
赛腾制药 |
白细胞介素15变体
|
|
JP7690131B2
(ja)
|
2022-01-04 |
2025-06-09 |
フィロジェン ソチエタ ペル アツィオーニ |
Ｉｌ－１２を含むイムノサイトカインとキナーゼ阻害剤の組合せ
|
|
US12576154B2
(en)
|
2022-08-01 |
2026-03-17 |
Philochem Ag |
Conjugates of PSMA-binding moieties with cytotoxic agents
|
|
CN119836298A
(zh)
|
2022-09-01 |
2025-04-15 |
菲洛根股份公司 |
用于非黑色素瘤皮肤癌的TNFα和白细胞介素-2组合疗法
|
|
CA3266566A1
(en)
|
2022-09-06 |
2024-03-14 |
Philochem Ag |
MULTIVALENT FIBROBLAST ACTIVATING PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS
|
|
WO2025061801A1
(en)
|
2023-09-19 |
2025-03-27 |
Philochem Ag |
Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
|
|
WO2026003203A1
(en)
|
2024-06-27 |
2026-01-02 |
Philogen S.P.A. |
Combination of an immunocytokine comprising targeted il2 and a jak inhibitor
|